Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6318)
All Articles published online
|
Publishing Process of This Article
|
May 21, 2016 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kalambokis GN, Baltayiannis G, Christodoulou D. von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis. World J Gastroenterol 2016; 22(19): 4786-4788 [PMID: 27217711 DOI: 10.3748/wjg.v22.i19.4786] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v22/i19/4786.htm |
| Number | Citing Articles |
| 1 |
Xuchen Zhang, Courtney Thomas, Thomas D Schiano, Swan N Thung, Stephen C Ward, M Isabel Fiel. Aberrant von Willebrand factor expression of sinusoidal endothelial cells and quiescence of hepatic stellate cells in nodular regenerative hyperplasia and obliterative portal venopathy. Histopathology 2020; 76(7): 959 doi: 10.1111/his.14083
|
| 2 |
Nicoleta State, Victor Stoica. Antithrombotic Drugs in Cirrhosis. Internal Medicine 2020; 17(6): 7 doi: 10.2478/inmed-2020-0138
|
| 3 |
Karoline Rutter, Alexandra Etschmaier, Monika Ferlitsch, Andreas Maieron, Stephanie Hametner, Thomas Horvatits, Rafael Paternostro, Petra Salzl, Thomas Reiberger, Markus Peck-Radosavljevic, Peter Quehenberger, Harald Hofer, Michael Trauner, Peter Ferenci, Arnulf Ferlitsch. von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. Digestive and Liver Disease 2016; 48(10): 1194 doi: 10.1016/j.dld.2016.06.033
|